Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Federal Trade Commission
US Department of Justice
Daiichi Sankyo
Moodys
Colorcon
Cantor Fitzgerald
Johnson and Johnson
QuintilesIMS
Novartis

Generated: February 23, 2018

DrugPatentWatch Database Preview

Melinta Company Profile

« Back to Dashboard

Summary for Melinta
International Patents:97
US Patents:17
Tradenames:2
Ingredients:2
NDAs:3

Drugs and US Patents for Melinta

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Melinta BAXDELA delafloxacin meglumine TABLET;ORAL 208610-001 Jun 19, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up
Melinta BAXDELA delafloxacin meglumine POWDER;IV (INFUSION) 208611-001 Jun 19, 2017 RX Yes Yes 8,410,077 ➤ Sign Up Y ➤ Sign Up
Melinta BAXDELA delafloxacin meglumine TABLET;ORAL 208610-001 Jun 19, 2017 RX Yes Yes 8,871,938 ➤ Sign Up Y ➤ Sign Up
Melinta BAXDELA delafloxacin meglumine TABLET;ORAL 208610-001 Jun 19, 2017 RX Yes Yes 8,969,569 ➤ Sign Up Y ➤ Sign Up
Melinta ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes 8,420,592 ➤ Sign Up ➤ Sign Up
Melinta ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up
Melinta BAXDELA delafloxacin meglumine TABLET;ORAL 208610-001 Jun 19, 2017 RX Yes Yes 9,539,250 ➤ Sign Up Y Y ➤ Sign Up
Melinta ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes 9,682,061 ➤ Sign Up ➤ Sign Up
Melinta BAXDELA delafloxacin meglumine POWDER;IV (INFUSION) 208611-001 Jun 19, 2017 RX Yes Yes 8,648,093 ➤ Sign Up Y ➤ Sign Up
Melinta BAXDELA delafloxacin meglumine POWDER;IV (INFUSION) 208611-001 Jun 19, 2017 RX Yes Yes 8,871,938 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Melinta

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Melinta ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 5,840,684 ➤ Sign Up
Melinta ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 5,998,581 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Melinta Drugs

Supplementary Protection Certificates for Melinta Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90041-7 Sweden ➤ Sign Up PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323
/2016 Austria ➤ Sign Up PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
0834 Netherlands ➤ Sign Up PRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323
2016000075 Germany ➤ Sign Up PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319
16/040 Ireland ➤ Sign Up PRODUCT NAME: ORITAVANCIN AND PHARMACEUTICAL SALTS THEREOF, E.G DIPHOSPHATE SALTS; REGISTRATION NO/DATE: EU/1/15/989 20150319
2016 00044 Denmark ➤ Sign Up PRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Army
Chinese Patent Office
Citi
McKesson
US Department of Justice
QuintilesIMS
Deloitte
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot